Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular and Genetic Changes in Resectable NSCLC Following Neoadjuvant Vinorelbine and Gemcitabine
NCT00057798Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2000
- Primary completion
- May 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vinorelbine, gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Roswell Park Comprehensive Cancer Center. Started Mar 2000; status: completed.
02
Drugs
vinorelbinegemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00057798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057798.